Tag: Weekly GLP-1 Fc fusion

  • Dulaglutide

    Weekly GLP-1 Fc fusion

    A GLP-1 analog fused to human IgG4 Fc for weekly dosing, FDA-approved as Trulicity for T2DM.

    Abstract

    Dulaglutide (Trulicity; CAS 923950-08-7; molecular weight ~63000) is an IgG4-Fc fusion protein containing two modified GLP-1(7-37) sequences. The Fc fusion provides extended half-life of approximately 5 days through neonatal Fc receptor recycling, supporting once-weekly subcutaneous dosing. The compound was developed by Eli Lilly and approved by the FDA in 2014 for T2DM. The cardiovascular outcomes program (REWIND) demonstrated MACE reduction in T2DM patients with cardiovascular risk factors.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.